

1 **Detection of Air and Surface Contamination by Severe Acute Respiratory Syndrome**
2 **Coronavirus 2 (SARS-CoV-2) in Hospital Rooms of Infected Patients**

3 Po Ying Chia, MBBS^{1,2,3*}; Kristen Kelli Coleman, PhD^{4*}; Yian Kim Tan, PhD^{5*}; Sean Wei
4 Xiang Ong^{1,2*}; Marcus Gum, BSc⁵; Sok Kiang Lau, PhD⁵; Stephanie Sutjipto, MBBS^{1,2}; Pei
5 Hua Lee, MBBS^{1,2}; Than The Son, DVM⁴; Barnaby Edward Young, MB Bchir^{1,2,3}; Donald
6 K. Milton, MD, DrPH⁶; Gregory C. Gray, MD^{4,7,8}; Stephan Schuster, PhD⁹; Timothy
7 Barkham, MBBS^{2,10}; Partha Prathim De, MBBS^{2,3}; Shawn Vasoo, MBBS^{1,2,3}; Monica Chan,
8 BMBS^{1,2}; Brenda Sze Peng Ang, MBBS, MPH^{1,2,3,10}; Boon Huan Tan, PhD⁵; Yee-Sin Leo,
9 MBBS, MPH^{1,2,3,10}; Oon-Tek Ng, MBBS, MPH^{1,2,3#}; Michelle Su Yen Wong, PhD^{5#}; and
10 Kalisvar Marimuthu, MBBS^{1,2,10#}

11 * These four first authors contributed equally.

12 # These three senior authors contributed equally.

13 **Author Affiliations:**

14 ¹ National Centre for Infectious Diseases, Singapore

15 ² Tan Tock Seng Hospital, Singapore

16 ³ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

17 ⁴ Duke-NUS Medical School, National University of Singapore

18 ⁵ DSO National Laboratories, Singapore

19 ⁶ Maryland Institute for Applied Environmental Health, University of Maryland School of
20 Public Health, USA

21 ⁷ School of Medicine and Global Health Institute, Duke University, USA

22 ⁸ Global Health Research Center, Duke Kunshan University, Kunshan, China

23 ⁹ Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological
24 University, Singapore

25 ¹⁰ Yong Loo Lin School of Medicine, National University of Singapore

26 **Corresponding Authors:**

27 Kalisvar Marimuthu, National Centre for Infectious Diseases, 16 Jln Tan Tock Seng,
28 Singapore 308442; (kalisvar_marimuthu@ncid.sg) (+65) 6357 7924)

29 Oon-Tek Ng, National Centre for Infectious Diseases, 16 Jln Tan Tock Seng, Singapore
30 308442; (Oon_Ng_Tek@ncid.sg) (+65) 6357 7924)

31 **Running Title:** Air and surface contamination by SARS-CoV-2

32 **Word Count:** 270 (abstract), 2456 (manuscript)

33 **Abstract:**

34 **Background:** Understanding the particle size distribution in the air and patterns of
35 environmental contamination of SARS-CoV-2 is essential for infection prevention policies.

36 **Objective:** To detect the surface and air contamination by SARS-CoV-2 and study the
37 associated patient-level factors.

38 **Design:** Cross-sectional study.

39 **Setting:** Airborne infection isolation rooms (AIIRs) at the National Centre for Infectious
40 Diseases, Singapore.

41 **Patients:** COVID-19 inpatients with a positive PCR test for SARS-CoV-2 within 72 hours
42 before the environmental sampling.

43 **Measurements:** Extent of environmental surface contamination in AIIRs of 30 COVID-19
44 patients by PCR on environmental swabs. The particle size distribution of SARS-CoV-2 in
45 the air was measured using NIOSH air samplers.

46 **Results:** 245 surface samples were collected from 30 rooms of COVID-19 patients, and air
47 sampling was conducted in 3 rooms. 56.7% of the rooms had at least one environmental
48 surface contaminated, with 18.5% of the toilet seats and toilet flush button being
49 contaminated. High touch surface contamination was shown in ten (66.7%) out of 15 patients
50 in the first week of illness, and three (20%) beyond the first week of illness ($p = 0.010$). Air
51 sampling of two COVID-19 patients (both day 5 of symptoms) detected SARS-CoV-2 PCR-
52 positive particles of sizes $>4 \mu\text{m}$ and $1-4 \mu\text{m}$. In a single subject at day 9 of symptoms, no
53 SARS-CoV-2 PCR-positive particles were detected.

54 **Limitations:** Viral culture results were not available to assess the viability of the virus
55 contaminating the air and surface.

56 **Conclusion:** Environmental contamination was detected in rooms with COVID-19 patients in
57 early stages of illness, but was significantly less after day 7 of disease. Under AIIR
58 conditions, SARS-CoV-2 respiratory particles can be detected at sizes 1-4 μm and $>4 \mu\text{m}$ in
59 diameter in the air which warrants further studies.

60 **Introduction**

61 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease
62 2019 (COVID-19) has spread globally and many countries are experiencing ongoing local
63 transmission despite varying levels of control efforts. Understanding the different
64 transmission routes of SARS-CoV-2 is crucial in planning effective interventions to break the
65 chain of transmission. Although extensive surface contamination with SARS-CoV-2 by a
66 symptomatic patient has been demonstrated (1), little is known about airborne transmission of
67 SARS-CoV-2. It is also unknown if asymptomatic individuals pose the same environmental
68 contamination risk as symptomatic ones, although viral shedding has been demonstrated to
69 continue even after clinical recovery of COVID-19 patients (2). There are multiple reports of
70 asymptomatic patients testing positive for SARS-CoV-2 (3, 4), and the potential transmission
71 of the virus by an asymptomatic person has been described (5). Therefore, viral
72 contamination of the air and surfaces surrounding asymptomatic or recovering COVID-19
73 patients could have serious implications for outbreak control strategies. This knowledge gap
74 is recognized in the Report of the WHO-China Joint Mission on Coronavirus 2019 (6).

75 The primary objective of our study was to identify potential patient-level risk factors for
76 environmental contamination by SARS-CoV-2 by sampling the air and surfaces surrounding
77 hospitalized COVID-19 patients at different stages of illness.

78 **Methods**

79 **Study design, patient selection and data collection**

80 We conducted this cross-sectional study in airborne infection isolation rooms (AIIRs) at the
81 National Centre for Infectious Diseases, Singapore. These rooms had 12 air exchanges per
82 hour, an average temperature of 23°C, relative humidity of 53 – 59%, and exhaust flow of
83 579.6 m³/h.

84 Patients with a SARS-CoV-2 infection confirmed by a polymerase chain reaction (PCR)-
85 positive respiratory sample within the prior 72 hours were included. Clinical characteristics,
86 including the presence of symptoms, day of illness, day of stay in the room, supplemental
87 oxygen requirement, and baseline characteristics, were collected. One patient from a
88 previously published pilot study on environmental sampling in the same facility (Patient 30;
89 Supplemental Table 1) was also included in the current analysis (1).

90 **Cleaning regimen of rooms**

91 Routine environmental cleaning of the rooms was carried out by a trained team of
92 housekeeping staff. High-touch surfaces (e.g. bed rail, cardiac table, switches) were cleaned
93 twice daily using 5000 parts per million (ppm) sodium dichloroisocyanurate (NaDCC),
94 reconstituted using Biospot[®] Effervescent Chlorine Tablets. The floor was cleaned daily
95 using 1000ppm NaDCC. All surface sampling was performed in the morning before the first
96 cleaning cycle for the day.

97 **Air sampling**

98 Six NIOSH BC 251 bioaerosol samplers were placed in each of three AIIRs in the general
99 ward to collect air samples. Particles collected with the NIOSH sampler are distributed into
100 three size fractions. Particles $>4 \mu\text{m}$ in diameter are collected in a 15 mL centrifuge tube,
101 particles 1-4 μm in diameter are collected in a 1.5 mL centrifuge tube, and particles $<1 \mu\text{m}$ in
102 diameter are collected in a self-assembled filter cassette containing a 37-mm diameter,
103 polytetrafluoroethylene (PTFE) filter with $3\mu\text{m}$ pores. All NIOSH samplers were connected
104 to either SKC AirCheck TOUCH Pumps or SKC Universal air sampling pumps set at a flow-
105 rate of 3.5 L/min and run for four hours, collecting a total of 5,040 L of air from each
106 patient's room.

107 In the room of Patient 1, three NIOSH samplers were attached to each of two tripod stands
108 and situated at different heights from the ground (1.2m, 0.9m, and 0.7m) near the air exhaust
109 to capture particles from the unidirectional airflow in the room. Throughout the four-hour
110 sampling period, Patient 1 was intermittently facing the NIOSH samplers while seated one
111 meter from the first tripod and 2.1 meters from the second tripod. Four SKC 37mm PTFE
112 filter (0.3 μ m pore size) cassettes were also distributed throughout the room and connected to
113 SKC Universal air sampling pumps set at a flow-rate of 5 L/min, each collecting an
114 additional 1,200 L of air from the room.

115 In the rooms of Patients 2 and 3, three NIOSH samplers were attached to each of two tripod
116 stands and situated at different heights from the ground (1.2m, 0.9m, and 0.7m). Throughout
117 the four-hour sampling period, Patients 2 and 3 remained in bed within 1 meter from all 6
118 NIOSH samplers (Supplementary Figure 1). Patient 3 was also talking on the phone for a
119 significant proportion of time during sampling. Additional SKC pumps with PTFE filter
120 cassettes were not used in the rooms of Patient 2 and 3.

121 The 6 NIOSH samples from each room were pooled prior to analysis, but the particle size
122 fractions remained separated. Each sample pool was representative of 5,040 L air.

123 **Surface sampling**

124 Surface samples were collected with Puritan® EnviroMax Plus pre-moistened macrofoam
125 sterile swabs (25-88060). Eight to 20 surface samples were collected in each room. Five were
126 high-touch surfaces, including the cardiac table, entire length of the bed rails including bed
127 control panel and call bell, bedside locker, electrical switches on top of the beds, and chair in
128 general ward rooms (Supplemental Figure 1). In ICU rooms, the ventilator and infusion
129 pumps were sampled instead of the electrical switches on top of the beds and chair
130 (Supplemental Figure 2). Air exhaust outlets and glass window surfaces were sampled in five

131 rooms, including the three rooms in which air sampling was performed. Toilet seat and
132 automatic flush button (one combined swab) were sampled in AIIR rooms in the general
133 ward.

134 **Sample transfer and processing**

135 All samples were immediately stored at 4°C in the hospital prior to transfer to a BSL-3
136 laboratory where samples were immediately processed and stored at -80°C unless directly
137 analyzed. Prior to RNA extraction, NIOSH aerosol sample tubes and filters were processed as
138 previously described (7), with slight modification due to the pooling of samples.

139 **Laboratory methods**

140 The QIAamp viral RNA mini kit (Qiagen Hilden, Germany) was used for sample RNA
141 extraction. Real-time PCR assays targeting the envelope (E) genes (8) and an in house orflab
142 assay were used to detect SARS-CoV-2 in the samples (9). All samples were run in duplicate
143 and with both assays. Positive detection was recorded as long as amplification was observed
144 in at least 1 assay.

145 **Statistical analysis**

146 Statistical analysis was performed using Stata version 15.1 (StataCorp, College Station,
147 Texas) and GraphPad Prism 8.0 (GraphPad Software, Inc., San Diego). $P < 0.05$ was
148 considered statistically significant, and all tests were 2-tailed. For the surface environment,
149 outcome measures analyzed were any positivity by room and pooled percentage positivity by
150 day of illness and respiratory viral load (represented by clinical cycle threshold (Ct) value).
151 We analyzed the factors associated with environmental contamination using the Student t-
152 test, or the nonparametric Wilcoxon rank-sum test was used for continuous variables
153 depending on their distribution. The χ^2 or Fisher exact test was used to compare categorical

154 variables. We plotted the best fit curve by least-square method to study the environmental
155 contamination distribution across various the days of illness and clinical Ct value.

156 **Results**

157 Environmental sampling was conducted in three AIIRs in the ICU and 27 AIIRs in the
158 general ward. Air sampling was performed in three of the 27 AIIRs in the general ward. All
159 patients reported COVID-19 symptoms. Seven patients (23%) were asymptomatic at the time
160 of environmental sampling. Of the 23 symptomatic patients, 18 (78%) had respiratory
161 symptoms, one had gastrointestinal symptoms, one had both respiratory and gastrointestinal
162 symptoms, and three patients (10%) had fever or myalgia only (Supplemental Table 1).

163 There were no baseline differences between patients with environmental surface
164 contamination and those without, in terms of age, comorbidities, and positive clinical sample
165 on the day of sampling. Median cycle threshold (Ct) values of the clinical specimens for
166 patients with and without environmental surface contamination were 25.69 (IQR 20.37 to
167 34.48) and 33.04 (28.45 to 35.66) respectively (Table 1).

168 Of the rooms with environmental contamination, the floor was most likely to be contaminated
169 (65%), followed by the bed rail (59%), and bedside locker (42%) (Figure 1). Contamination
170 of toilet seat and automatic toilet flush button was detected in five out of 27 rooms, and all
171 five occupants had reported gastrointestinal symptoms within the preceding one week of
172 sampling. We did not detect surface contamination in any of the three ICU rooms.

173 Presence of environmental surface contamination was higher in week 1 of illness (Figure 2)
174 and showed association with the clinical cyclical threshold ($P=0.06$). Surface environment
175 contamination was not associated with the presence of symptoms or supplementary oxygen
176 (Table 1). In a subgroup analysis, the presence and extent of high-touch surface
177 contamination were significantly higher in rooms of patients in their first week of illness

178 (Figure 2). The best fit curve with the least-squares fit (Figure 3) showed that the extent of
179 high-touch surface contamination declined with increasing duration of illness and Ct values.
180 There was also no correlation between the Ct values of clinical samples and the Ct values of
181 environmental samples across the days of illness (Supplemental Figure 3).

182 Air samples from two (66.7%) of three AIIRs tested positive for SARS-CoV-2, in particle
183 sizes $>4 \mu\text{m}$ and $1-4 \mu\text{m}$ in diameter (Table 1). Total SARS-CoV-2 concentrations in air
184 ranged from 1.84×10^3 to 3.38×10^3 RNA copies per m^3 air sampled. Rooms with viral
185 particles detected in the air also had surface contamination detected.

186 **Discussion**

187 Surface sampling revealed that the PCR-positivity high-touch surfaces was associated with
188 nasopharyngeal viral loads and peaked at approximately day four to five of symptoms. Air
189 sampling of the AIIR environments of two COVID-19 patients (both day five of illness with
190 high nasopharyngeal swab viral loads) detected the presence of SARS-CoV-2 particles sized
191 $1-4 \mu\text{m}$ and $> 4 \mu\text{m}$. The absence of any detection of SARS-CoV-2 in air samples of the third
192 patient (day nine of illness with lower nasopharyngeal viral load concentration) suggests that
193 the presence of SARS-CoV-2 in the air is possibly highest in the first week of illness.

194 Recent aggregated environmental sampling and laboratory experiments have examined the
195 particle size distribution of SARS-CoV-2 in the air. A study from Wuhan, China sampled
196 three different environmental settings and detected aerosol size range particles (10).

197 Additionally, a recent laboratory study demonstrated the ability of SARS-CoV-2 to remain
198 viable in aerosols for up to 3 hours (11). While limited in subject numbers, our study
199 examined this issue at the individual patient-level, thus enabling correlation of particle size
200 distribution in the air with symptoms duration and nasopharyngeal viral loads. The absence of
201 aerosol-generating procedures or intranasal oxygen supplementation reduces the possibility

202 of our current findings being iatrogenic in nature. Larger individual patient-level studies
203 examining the droplet and aerosolizing potential of SARS-CoV-2 over different distances and
204 under different patient and environmental conditions are rapidly needed to determine the
205 generalizability of our current findings.

206 In the current analysis the presence and concentration of SARS-CoV-2 in air and high-touch
207 surface samples correlated with the day of illness and nasopharyngeal viral loads of COVID-
208 19 patients. This finding is supported by multiple observational clinical studies have
209 demonstrated that SARS-CoV-2 viral loads peak in the first week among COVID-19 patients
210 (2, 12, 13). This finding could help inform public health and infection prevention measures in
211 prioritizing resources by risk stratifying COVID-19 patients by their potential to directly or
212 indirectly transmit the SARS-CoV-2 virus to others.

213 Our study was limited in that it did not determine the ability of SARS-CoV-2 to be cultured
214 from the environmental swabs and the differentially-sized air particles which would be vital
215 to determining the infectiousness of the detected particles. Another study from Nebraska
216 attempted virus culture on SARS-CoV-2 PCR-positive air samples, however could not isolate
217 viable virus (14). The difficulty in culturing virus from air samples arises from low virus
218 concentrations, as well as the compromised integrity of the virus due to air sampling
219 stressors. Future studies using enhanced virus culture techniques could be considered (15),
220 and efforts to design a culture method to isolate virus from our samples is underway. Second,
221 sampling in an AIIR environment may not be representative of community settings and
222 further work is needed to generalize our current findings. Third, we sampled each room at a
223 single timepoint during the course of illness and did not track environmental contamination
224 over the course of illness for individual patients. Fourth, as clinical results were within 72
225 hours of environmental testing, it is plausible that during the day of testing, viral load was
226 actually low or negligible, hence limiting environmental contamination.

227 Current epidemiologic evidence does not seem to point to aerosolization as the key route of
228 transmission of SARS-CoV-2 (16). Detailed epidemiologic studies of outbreaks, in both
229 healthcare and non-healthcare settings, should be carried out to determine the relative
230 contribution of various routes of transmission and their correlation with patient-level factors.

231 In conclusion, in a limited number of AIIR environments, our current study involving
232 individual COVID-19 patients not undergoing aerosol-generating procedures or oxygen
233 supplementation suggest that SARS-CoV-2 can be shed in the air from a patient in particles
234 sized between 1 to 4 microns. Even though particles in this size range have the potential to
235 linger longer in the air, more data on viability and infectiousness of the virus would be
236 required to confirm the potential airborne spread of SARS-CoV-2. Additionally, the
237 concentrations of SARS-CoV-2 in the air and high-touch surfaces could be highest during the
238 first week of COVID-19 illness. Further work is urgently needed to examine these findings in
239 larger numbers and different settings to better understand the factors affecting air and surface
240 spread of SARS-CoV-2 and inform effective infection prevention policies.

241 **Acknowledgements**

242 We thank Dr Bill Lindsley (National Institute for Occupational Safety and Health, NIOSH)
243 for loaning us aerosol samplers and guiding us in their use; Dr. Raquel Binder and Emily
244 Robie from the Duke One Health team for quickly providing us equipment for use in this
245 study; Dr Hsu Li Yang (Saw Swee Hock School of Public Health, National University of
246 Singapore) for facilitating the air sampling; and Dr Ding Ying (National Centre for Infectious
247 Diseases, Singapore) for helping with project coordination. No compensation was received
248 for their roles in the study.

249 We further thank the colleagues in DSO National Laboratories in the environmental detection
250 team and clinical diagnostics team for BSL3 sample processing and analysis as well as the
251 logistics and repository team for transport of biohazard material, inventory and safekeeping
252 of received items.

253

254 **Conflict of Interest Disclosures**

255 None reported.

256

257 **Funding**

258 This study is funded by NMRC Seed Funding Program (TR19NMR119SD), NMRC COVID-
259 19 Research Fund (COVID19RF-001) and internal funds from DSO National Laboratories.
260 Ng OT is supported by NMRC Clinician Scientist Award (MOH-000276). K Marimuthu is
261 supported by NMRC CS-IRG (CIRG18Nov-0034). Chia PY is supported by NMRC
262 Research Training Fellowship (NMRC/Fellowship/0056/2018).

263

264 **Role of Funder/Sponsors**

265 The funders had no role in the design and conduct of the study; collection, management,
266 analysis and interpretation of the data; preparation, review or approval of the manuscript; and
267 decision to submit the manuscript for publication.

268 **References**

- 269 1. Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, Surface
270 Environmental, and Personal Protective Equipment Contamination by Severe Acute
271 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient.
272 JAMA. 2020.
- 273 2. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic
274 Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.
275 JAMA. 2020.
- 276 3. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of
277 pneumonia associated with the 2019 novel coronavirus indicating person-to-person
278 transmission: a study of a family cluster. *The Lancet*. 2020.
- 279 4. Pan X, Chen D, Xia Y, Wu X, Li T, Ou X, et al. Asymptomatic cases in a family
280 cluster with SARS-CoV-2 infection. *Lancet Infect Dis*. 2020.
- 281 5. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed Asymptomatic Carrier
282 Transmission of COVID-19. *JAMA*. 2020.
- 283 6. WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019
284 (COVID-19). 2020.
- 285 7. Coleman KK, Sigler WV. Airborne Influenza A Virus Exposure in an Elementary
286 School. *Scientific Reports*. 2020;10(1):1859.
- 287 8. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection
288 of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*.
289 2020;25(3):2000045.
- 290 9. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic
291 Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.
292 JAMA. 2020.

- 293 10. Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, et al. Aerodynamic Characteristics
294 and RNA Concentration of SARS-CoV-2 Aerosol in Wuhan Hospitals during
295 COVID-19 Outbreak. *BioRxiv*. 2020.
- 296 11. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson
297 BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-
298 CoV-1. *New England Journal of Medicine*. 2020.
- 299 12. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load
300 in Upper Respiratory Specimens of Infected Patients. *N Engl J Med*. 2020.
- 301 13. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in
302 Different Types of Clinical Specimens. *JAMA*. 2020.
- 303 14. Santarpia JL, Rivera DN, Herrera V, Morwitzer MJ, Creager H, Santarpia GW, et al.
304 Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University
305 of Nebraska Medical Center. *medRxiv*. 2020.
- 306 15. Cao G, Noti J, Blachere F, Lindsley W, Beezhold D. Development of an improved
307 methodology to detect infectious airborne influenza virus using the NIOSH bioaerosol
308 sampler. *Journal of Environmental Monitoring*. 2011;13(12):3321-8.
- 309 16. Ng K, Poon BH, Kiat Puar TH, Shan Quah JL, Loh WJ, Wong YJ, et al. COVID-19
310 and the Risk to Health Care Workers: A Case Report. *Ann Intern Med*. 2020.

311

312 **Tables & Figures**

313 **Table 1. Airborne severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)**
314 **detections in hospital rooms of infected patients**

Patient	Day of illness	Symptoms on day of air sampling	Clinical Ct value*	Airborne SARS-CoV-2 concentrations (RNA copies m⁻³ air)	Aerosol particle size	Samplers used
1	9	Cough, nausea, dyspnea	33.22	ND	--	NIOSH
				ND	--	SKC Filters
2	5	Cough, dyspnea	18.45	2,000	>4 μm	NIOSH
				1,384	1-4 μm	
3	5	Asymptomatic [†]	20.11	927	>4 μm	NIOSH
				916	1-4 μm	

ND = none detected

*PCR cycle threshold value from patient's clinical sample

[†]Patient reported fever, cough, and sore throat until the day before the sampling. Patient reported no symptoms on the day of sampling, however was observed to be coughing during sampling


316 **Table 2: Baseline clinical characteristics of COVID-19 patients with environmental**
317 **contamination**

	With surface environment contamination (n=17)	Without surface environment contamination (n=13)	P-value
Median age (IQR)	52 (42 to 62)	44 (36 to 55)	0.7535
Male Sex (%)	6 (46%)	8 (47%)	0.961
Median Age Adjusted Charlson's Comorbidity Index (IQR)	1 (0 to 2)	1 (0 to 1)	0.6924
Median day of Illness (IQR)	5 (4 to 9)	13 (5 to 20)	0.1715
Median day of stay in room (IQR)	3 (3 to 8)	4 (2 to 16)	0.9491
Oxygen requirement (%)	0	4 (31)	0.026
Symptomatic (%)	12 (71)	11 (85)	0.427
Respiratory symptoms (%)	11 (65)	7 (54)	0.547
Gastrointestinal symptoms (%)	1 (6)	1 (8)	1.000
Clinical Cycle threshold value, median (IQR)*	25.69 (20.37 to 34.48)	33.04 (28.45 to 35.66)	0.056

318 *PCR cycle threshold value from patient's clinical sample

319

320 **Figure 1: Percentage of contaminated swabs from surface samples, in rooms with any**
321 **contamination**



322 All other sites were n=17, except for air exhaust vents where n=5

323

324

325

326


327

328



329

330


331 **Figure 2: 2a. Percentage of patients with contamination of high touch surfaces in in the**
332 **first week of illness compared with more than first week of illness. 2b. Percentage of**
333 **surfaces contaminated across weeks of illness. 2c. Percentage of high-touch surfaces**
334 **contaminated across weeks of illness**



336 **Figure 3: 3a. Mean percentage of high touch surface contaminated by day of illness with**
337 **95% confidence interval with best fit curve. 3b. Percentage of high touch surfaces**
338 **contaminated by clinical cycle threshold values with best fit curve. 3c. Mean percentage**
339 **of high touch surface contaminated by day of illness with 95% confidence interval**



340 **grouped by symptoms**



341

342

343

344

345